Therapeutic products containing CD8+ and CD4+ T cells expressing CARs are effective at inducing remission in patients with cancer. How CD4+ CAR T cells contribute to the anti-tumor response has not been well established. A study uses syngeneic models and in vivo imaging to glean mechanistic insights into how CD4+ T cells target tumors.
- M. Eric Kohler
- Terry J. Fry
